| 摘要 |
The use is described of both (i) [1R-[1 alpha (Z),2 beta , 3 beta ,5 alpha ]]-(+)-7-[5-[[(1,1'-biphenyl)-4-yl]methoxy]-3-hydroxy-2-(1-piperidinyl) cyclopentyl]-4-heptenoic acid or a physiologically acceptable salt or solvate thereof and (ii) a thromboxane synthase inhibitor, either separately or in combination in the therapy or prophylaxis of occlusive vascular diseases in humans. Pharmaceutical compositons containing both (i) and (ii) are also described. |
